Key result
Coxsackievirus A16 infection linked to ~2.3-fold faster viral clearance vs CVA10 in HFMD.
Why the study?
Does Coxsackievirus A16 infection differ from Coxsackievirus A10 infection in viral RNA shedding duration and clinical manifestations in children with hand, foot, and mouth disease?
Cohort (n=63)
Yes
Does Coxsackievirus A16 infection differ from Coxsackievirus A10 infection in viral RNA shedding duration and clinical manifestations in children with hand, foot, and mouth disease?
Children with CVA10-associated hand, foot, and mouth disease shed viral RNA significantly longer than those with CVA16 (median 9.5 vs 8.0 days), while 91.7% of symptomatic children clear viral RNA within 5 days of symptom resolution, supporting potential refinement of current 7-day post-symptom isolation guidelines.
May inform serotype-specific isolation in HFMD; extends shedding data beyond EV-A71 to dominant strains.
Background Hand, foot, and mouth disease (HFMD) remains a major and persistent public health challenge in China and across many parts of Asia. Following widespread implementation of enterovirus A71 vaccination in China, coxsackievirus A10 (CVA10) and coxsackievirus A16 (CVA16) have emerged as the dominant serotypes associated with outbreaks in children. Objective To investigate the viral shedding duration and clinical differences of CVA10 and CVA16 in HFMD outbreaks in Jiangsu Province, and to generate evidence for optimizing case management and outbreak control. Methods In 2024, a total of 63 HFMD cases were prospectively followed daily to monitor symptom progression. Pharyngeal swabs were collected once at symptom onset and on days 3, 7, 10, and 14 post-onset from cases and close contacts. All specimens were tested by RT-PCR for nucleic acid detection and serotype identification. Results CVA10-infected children had a significantly longer duration (9.5 days) than those with CVA16 (8.0 days, P = 0.012). CVA16 infection correlated with more symptomatic cases, especially higher rash incidence, and increased healthcare-seeking behavior. Viral load dropped sharply from days 1–4, and symptom duration was positively correlated with viral shedding duration in symptomatic children (r = 0.33); 91.7% of children tested negative within 5 days after symptom resolution. Conclusions This study suggests that symptom resolution may provide a potential reference for evaluating isolation strategies, early monitoring is critical due to rapid viral load decline, and symptom duration may serve as an indicator of viral RNA shedding duration. Given CVA10’s prolonged viral shedding and CVA16’s symptom-driven transmission, serotype-specific and tailored management strategies may be valuable for HFMD control. However, infectivity was not directly assessed, and these findings should be further validated using viral culture.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) conducted a cohort in Hand, foot, and mouth disease (HFMD) (n=63). Coxsackievirus A16 (CVA16) infection vs. Coxsackievirus A10 (CVA10) infection was evaluated on Duration of viral RNA shedding in pharyngeal swabs (days to viral clearance) (HR 2.31, 95% CI 1.27-4.21, p=0.006). Coxsackievirus A16 infection had shorter median viral shedding than Coxsackievirus A10 (8.0 vs 9.5 days, P=0.012; multivariable HR 2.31, 95% CI 1.27-4.21, P=0.006) in children with HFMD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: